ArticleFrontiers in oncology2025
Survival improvement in primary plasma cell leukemia: a retrospective analysis of novel agent-based regimens and stem cell transplantation.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of Autologous Haematopoietic Transplantation in Leukaemias: When to Consider It in 2026.Hematology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to characterize the clinical profile and treatment outcomes of primary plasma cell leukemia (pPCL) patients, defined by ≥5% circulating plasma cells (CPCs) on peripheral blood smear, who received novel agent-based induction therapy. Methods: A retrospective analysis of 46 pPCL patients treated at Nanjing Drum Tower Hospital from March 2014 to April 2025 was conducted. Their clinical and laboratory manifestations, prognostic factors, and efficacy of induction therapies were focused upon. Results: Advanced-stage disease predominated in our cohort. The most frequent cytogenetic abnormalities were chromosome 1q21+ and del(13q14). Failure to achieve ≥very good partial response (VGPR) after first-line therapy independently predicted inferior overall survival (OS) (HR = 0.095, 95%CI 0.022-0.421, Conclusion: Despite novel agents, pPCL maintains poor prognosis, with treatment failure strongly associated with suboptimal first-line response. Therapeutic intensification through PIs/IMiDs with Ven (guided by t(11;14)) and ASCT consolidation may enhance depth of remission and survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.